JP4727748B2 - 神経保護医薬組成物の製造のためのプロインスリンの使用、それを含む治療組成物、およびそれらの応用 - Google Patents

神経保護医薬組成物の製造のためのプロインスリンの使用、それを含む治療組成物、およびそれらの応用 Download PDF

Info

Publication number
JP4727748B2
JP4727748B2 JP2009511534A JP2009511534A JP4727748B2 JP 4727748 B2 JP4727748 B2 JP 4727748B2 JP 2009511534 A JP2009511534 A JP 2009511534A JP 2009511534 A JP2009511534 A JP 2009511534A JP 4727748 B2 JP4727748 B2 JP 4727748B2
Authority
JP
Japan
Prior art keywords
proinsulin
nucleotide sequence
compound
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009511534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537612A5 (https=
JP2009537612A (ja
Inventor
エンリケ、ホタ．デ、ラ、ロサ、カノ
マリア、フロラ、デ、パブロ、ダビラ
パトリシア、ボヤ、トレモレダ
シルビア、コロチャノ、サンチェス
ペドロ、デ、ラ、ビリャ、ポロ
リマ、バルオウム、タンノウス
ファティマ、ボッシュ、トゥベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universitat Autonoma de Barcelona UAB, Universidad de Alcala de Henares UAH filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of JP2009537612A publication Critical patent/JP2009537612A/ja
Publication of JP2009537612A5 publication Critical patent/JP2009537612A5/ja
Application granted granted Critical
Publication of JP4727748B2 publication Critical patent/JP4727748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009511534A 2006-05-22 2007-05-21 神経保護医薬組成物の製造のためのプロインスリンの使用、それを含む治療組成物、およびそれらの応用 Expired - Fee Related JP4727748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200601314 2006-05-22
ES200601314A ES2331342B1 (es) 2006-05-22 2006-05-22 Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
PCT/ES2007/070097 WO2007135220A1 (es) 2006-05-22 2007-05-21 Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones

Publications (3)

Publication Number Publication Date
JP2009537612A JP2009537612A (ja) 2009-10-29
JP2009537612A5 JP2009537612A5 (https=) 2010-02-12
JP4727748B2 true JP4727748B2 (ja) 2011-07-20

Family

ID=38722988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511534A Expired - Fee Related JP4727748B2 (ja) 2006-05-22 2007-05-21 神経保護医薬組成物の製造のためのプロインスリンの使用、それを含む治療組成物、およびそれらの応用

Country Status (7)

Country Link
US (1) US20100330042A1 (https=)
EP (1) EP2042189B1 (https=)
JP (1) JP4727748B2 (https=)
AU (1) AU2007253212B2 (https=)
CA (1) CA2652983C (https=)
ES (2) ES2331342B1 (https=)
WO (1) WO2007135220A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL66610A (en) * 1981-08-27 1985-11-29 Lilly Co Eli Human proinsulin pharmaceutical formulations
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
DE69508605T2 (de) * 1994-07-08 1999-07-22 Trustees Of Dartmouth College, Hanover, N.H. Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
WO2000004171A1 (en) * 1998-07-15 2000-01-27 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003103608A2 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor

Also Published As

Publication number Publication date
CA2652983C (en) 2016-07-19
EP2042189A1 (en) 2009-04-01
ES2331342B1 (es) 2010-10-13
ES2433389T3 (es) 2013-12-10
ES2331342A1 (es) 2009-12-29
AU2007253212B2 (en) 2012-09-27
WO2007135220A1 (es) 2007-11-29
CA2652983A1 (en) 2007-11-29
AU2007253212A1 (en) 2007-11-29
EP2042189A4 (en) 2010-02-17
JP2009537612A (ja) 2009-10-29
EP2042189B1 (en) 2013-06-26
US20100330042A1 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
Petters et al. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa
Kobayashi et al. HRG4 (UNC119) mutation found in cone–rod dystrophy causes retinal degeneration in a transgenic model
JP7615238B2 (ja) 網膜ジストロフィーを治療するｒｄｈ１２コード領域を含むウイルスベクターおよび方法
US11351225B2 (en) Methods for modulating development and function of photoreceptor cells
Pang et al. AAV-mediated gene therapy in mouse models of recessive retinal degeneration
Palmer et al. Expression of Gtf2ird1, the Williams syndrome-associated gene, during mouse development
JP2018500906A (ja) 網膜変性処置のためのｏｔｘ２過剰発現トランスジェニック網膜色素上皮細胞
US20040055023A1 (en) Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
JP4727748B2 (ja) 神経保護医薬組成物の製造のためのプロインスリンの使用、それを含む治療組成物、およびそれらの応用
KR102168332B1 (ko) 망막색소변성증의 진단에 이용 가능한 15개의 ush2a 유전자 돌연변이체 및 이외 용도
WO1998015628A1 (fr) Nouveau gene de semaphorine: la semaphorine w
Wei Neural stem cell-based GDNF and CNTF for the treatment of retinal degeneration in a mouse model of CLN7 disease
Aguirre et al. The use of canine models to develop translational gene therapies for the treatment of six forms of inheritedretinal degenerationsb (Work conducted at the University of Pennsylvania-USA)
CA3082586C (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
HK40106588A (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
WO2005023311A2 (en) Novel targets for the treatment of retina diseases
RAKÓCZY et al. Eye diseases
HK40037202A (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
HK40037202B (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
Ramon et al. Molecular biology of retinitis pigmentosa: therapeutic implications
Lopes Characterization of human stem cells and therapeutic strategies involving IGF-1 and shRNA in Huntington's disease
EA049649B1 (ru) Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки
Beltran Cellular and molecular studies of ciliary neurotrophic factor receptor alpha expression and ciliary neurotrophic factor mediated neuroprotection in the canine retina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091214

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20091214

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110413

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140422

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees